Legal & General Group Plc lessened its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 6.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,904 shares of the biotechnology company's stock after selling 5,698 shares during the period. Legal & General Group Plc owned approximately 0.15% of Repligen worth $11,789,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of the business. Ballentine Partners LLC grew its holdings in Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after acquiring an additional 72 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock worth $246,000 after purchasing an additional 81 shares in the last quarter. MML Investors Services LLC increased its holdings in Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock valued at $503,000 after buying an additional 89 shares during the last quarter. GAMMA Investing LLC raised its stake in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after buying an additional 90 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock worth $2,087,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Repligen Stock Performance
RGEN stock traded down $2.10 during trading on Friday, hitting $130.00. The company had a trading volume of 753,355 shares, compared to its average volume of 708,300. The firm has a 50-day moving average price of $140.37 and a 200-day moving average price of $145.72. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.30 billion, a PE ratio of -254.90, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52.
Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million. On average, analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.
Insider Activity
In other news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company's stock.
Analysts Set New Price Targets
Several brokerages have recently weighed in on RGEN. StockNews.com lowered Repligen from a "hold" rating to a "sell" rating in a research report on Thursday. Royal Bank of Canada raised their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a report on Friday, February 21st. HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Repligen in a report on Friday, February 21st. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 price target on the stock. Finally, JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $176.82.
Check Out Our Latest Stock Report on Repligen
Repligen Company Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Articles
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
